Skandinaviska Enskilda Banken AB publ Sells 124,944 Shares of Catalent, Inc. (NYSE:CTLT)

Skandinaviska Enskilda Banken AB publ trimmed its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 78.4% in the second quarter, Holdings Channel.com reports. The firm owned 34,495 shares of the company’s stock after selling 124,944 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Catalent were worth $1,940,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in CTLT. Lindbrook Capital LLC boosted its stake in Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares during the period. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalent in the second quarter valued at about $42,000. Mather Group LLC. acquired a new position in shares of Catalent during the first quarter worth about $52,000. Longfellow Investment Management Co. LLC grew its holdings in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares in the last quarter.

Catalent Price Performance

NYSE:CTLT opened at $59.73 on Tuesday. The company has a current ratio of 2.52, a quick ratio of 1.77 and a debt-to-equity ratio of 1.35. The firm has a fifty day simple moving average of $59.52 and a 200 day simple moving average of $57.24. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20. The stock has a market capitalization of $10.81 billion, a PE ratio of -9.79, a P/E/G ratio of 1.88 and a beta of 1.15.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Thursday, August 29th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. On average, research analysts expect that Catalent, Inc. will post 1.06 EPS for the current fiscal year.

Insider Buying and Selling

In other Catalent news, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total value of $39,428.72. Following the sale, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Catalent news, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the transaction, the insider now directly owns 29,974 shares of the company’s stock, valued at $1,785,251.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Scott Gunther sold 666 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,409 shares of company stock worth $782,923. Company insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Barclays raised their target price on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Finally, StockNews.com began coverage on shares of Catalent in a research report on Wednesday, September 18th. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $58.08.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.